For the Inventor, By the Inventor

Enter assignee name

Stamford, CT, United States of America

Springworks Therapeutics, Inc.

USPTO Granted Patents = 41

EPO Patents = 2

Forward Citations = 87

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Kristin Patterson (27 out of 28 patents)

Todd Shearer (23 out of 23 patents)

Uchenna H Iloeje (14 out of 14 patents)

4. Abraham J Langseth (14 out of 14 patents)

5. Rex Williams (11 out of 11 patents)

6. Shinta Cheng (11 out of 11 patents)

7. Allison Lim (11 out of 11 patents)

8. Jiping Liu (9 out of 9 patents)

9. Mark Hatcher (8 out of 9 patents)

10. Ricky Wayne Couch (4 out of 10 patents)

11. Peter Gregory Varlashkin (4 out of 4 patents)

12. Mai Li (4 out of 4 patents)

13. Yonghong Gan (4 out of 4 patents)

14. Piero L Ruggiero (3 out of 3 patents)

15. Arnaud Marchand (2 out of 19 patents)

Core Competencies:

Mirdametinib

Nirogacestat

Neurofibromatosis Type 1

Plexiform Neurofibromas

YAP/TAZ-TEAD Inhibition

Dispersible Formulations

Crystalline Solids

Non-linear Dosing

Fluorinated Compounds

Chlorinated Compounds

Dosage Forms

Pharmaceutical Compositions

41 patents: Sort by Forward Citations

1. 12390430 - Mirdametinib treatment (2025-08-19),

2. 12383517 - Dosage forms of mirdametinib (2025-08-12),

3. 12378202 - Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD (2025-08-05),

4. 12357597 - Dispersible formulations of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof (2025-07-15),

5. 12324791 - Mirdametinib treatment (2025-06-10),

6. 12295925 - Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib (2025-05-13),

7. 12275688 - Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof (2025-04-14),

8. 12263146 - Non-linear dosing of mirdametinib (2025-04-01),

9. 12257215 - Mirdametinib treatment (2025-03-25),

10. 12247012 - Synthesis of nirogacestat (2025-03-11),

11. 12234210 - Synthesis of nirogacestat (2025-02-25),

12. 12220390 - Mirdametinib treatment (2025-02-11),

13. 12186305 - Treatments with nirogacestat (2025-01-07),

14. 12138246 - Treatments with nirogacestat (2024-11-12),

15. 12110277 - Synthesis of nirogacestat (2024-10-08),

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for patients suffering from severe rare diseases and cancer. Their innovative approach focuses on repurposing existing drugs to bring them to market faster and more cost-effectively. With a diverse pipeline of promising candidates, SpringWorks is working towards providing hope for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

41 Patents

#19 in Stamford, CT

#198 in Connecticut

#8,166 in US

#16,217 in the World

Stamford, CT, United States of America

Springworks Therapeutics, Inc.

Forward Citations = 87

22 inventors:

Kristin Patterson (27 out of 28 patents)

Todd Shearer (23 out of 23 patents)

Uchenna H Iloeje (14 out of 14 patents)

4. Abraham J Langseth (14 out of 14 patents)

5. Rex Williams (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…